595 related articles for article (PubMed ID: 17302253)
21. [Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].
Ma H; Ren JB; Li HY; Wang Y; Wang RL; Liang L; Sun SJ; Jia JD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):102-4. PubMed ID: 17653304
[TBL] [Abstract][Full Text] [Related]
22. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
[TBL] [Abstract][Full Text] [Related]
23. [Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area].
LI H; WANG ZY; ZHANG DZ; SHI XF; ZHOU Z; REN H
Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):338-41. PubMed ID: 19497197
[TBL] [Abstract][Full Text] [Related]
24. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma.
Wong DK; Yuen MF; Poon RT; Yuen JC; Fung J; Lai CL
J Hepatol; 2006 Oct; 45(4):553-9. PubMed ID: 16904225
[TBL] [Abstract][Full Text] [Related]
25. A review of entecavir in the treatment of chronic hepatitis B infection.
Rivkin A
Curr Med Res Opin; 2005 Nov; 21(11):1845-56. PubMed ID: 16307706
[TBL] [Abstract][Full Text] [Related]
26. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Chang TT; Chao YC; Gorbakov VV; Han KH; Gish RG; de Man R; Cheinquer H; Bessone F; Brett-Smith H; Tamez R
J Viral Hepat; 2009 Nov; 16(11):784-9. PubMed ID: 19457141
[TBL] [Abstract][Full Text] [Related]
27. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients.
Laras A; Koskinas J; Dimou E; Kostamena A; Hadziyannis SJ
Hepatology; 2006 Sep; 44(3):694-702. PubMed ID: 16941694
[TBL] [Abstract][Full Text] [Related]
28. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients.
Lin LY; Wong VW; Zhou HJ; Chan HY; Gui HL; Guo SM; Wang H; Huang L; Bao SS; Xie Q; Chan HL
J Med Virol; 2010 Sep; 82(9):1494-500. PubMed ID: 20648602
[TBL] [Abstract][Full Text] [Related]
29. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
[TBL] [Abstract][Full Text] [Related]
30. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
31. Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV-infected patients by LightCycler real-time PCR.
Singh M; Dicaire A; Wakil AE; Luscombe C; Sacks SL
J Virol Methods; 2004 Jun; 118(2):159-67. PubMed ID: 15081611
[TBL] [Abstract][Full Text] [Related]
32. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Colonno RJ; Rose R; Baldick CJ; Levine S; Pokornowski K; Yu CF; Walsh A; Fang J; Hsu M; Mazzucco C; Eggers B; Zhang S; Plym M; Klesczewski K; Tenney DJ
Hepatology; 2006 Dec; 44(6):1656-65. PubMed ID: 17133475
[TBL] [Abstract][Full Text] [Related]
33. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
34. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy.
Liu F; Chen L; Yu DM; Deng L; Chen R; Jiang Y; Chen L; Huang SY; Yu JL; Gong QM; Zhang XX
Gut; 2011 Sep; 60(9):1269-77. PubMed ID: 21292683
[TBL] [Abstract][Full Text] [Related]
35. Entecavir: a new treatment option for chronic hepatitis B.
Zoulim F
J Clin Virol; 2006 May; 36(1):8-12. PubMed ID: 16515882
[TBL] [Abstract][Full Text] [Related]
36. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.
Sung JJ; Wong ML; Bowden S; Liew CT; Hui AY; Wong VW; Leung NW; Locarnini S; Chan HL
Gastroenterology; 2005 Jun; 128(7):1890-7. PubMed ID: 15940624
[TBL] [Abstract][Full Text] [Related]
37. Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patients.
Takkenberg RB; Zaaijer HL; Menting S; Weegink CJ; Terpstra V; Cornelissen M; Dijkgraaf MG; Jansen PL; Reesink HW; Beld MG
Eur J Gastroenterol Hepatol; 2010 Aug; 22(8):952-60. PubMed ID: 20150816
[TBL] [Abstract][Full Text] [Related]
38. Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years.
Fung J; Lai CL; Yuen J; Cheng C; Wu R; Wong DK; Seto WK; Hung IF; Yuen MF
Hepatology; 2011 Apr; 53(4):1148-53. PubMed ID: 21480321
[TBL] [Abstract][Full Text] [Related]
39. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis.
Cheung CK; Lo CM; Man K; Lau GK
Liver Transpl; 2010 Nov; 16(11):1314-23. PubMed ID: 21031547
[TBL] [Abstract][Full Text] [Related]
40. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
Chan HL; Wang H; Niu J; Chim AM; Sung JJ
Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
